title: Suicidal erythrocyte death in end-stage renal disease.
abstract: Anemia in end-stage renal disease (ESRD) results mainly from erythropoietin and iron deficiency. Anemia could be confounded, however, by accelerated clearance of circulating erythrocytes because of premature suicidal erythrocyte death or eryptosis characterized by phosphatidylserine exposure at the erythrocyte surface. Triggers of eryptosis include increased cytosolic Ca(2+) concentration ([Ca(2+)]i), oxidative stress, and ceramide. The present study explored whether and how ESRD influences eryptosis. Blood was drawn from healthy volunteers (n = 20) as well as ESRD patients (n = 20) prior to and after hemodialysis. Phosphatidylserine exposure was estimated from annexin V binding, [Ca(2+)]i from Fluo3-fluorescence, reactive oxygen species (ROS) from 2',7'dichlorodihydrofluorescein fluorescence, and ceramide from fluorescein-isothiocyanate-conjugated antibody binding in flow cytometry. Measurements were made in erythrocytes from freshly drawn blood and in erythrocytes from healthy volunteers exposed in vitro for 24 h to plasma from healthy volunteers or ESRD patients prior to and following dialysis. The patients suffered from anemia (hemoglobin 10.1 ± 0.5 g/100 ml) despite 1.96 ± 0.34 % reticulocytes. The percentage of phosphatidylserine-exposing erythrocytes was significantly higher in ESRD patients (0.84 ± 0.09 %) than in healthy volunteers (0.43 ± 0.04 %) and was significantly increased immediately after dialysis (1.35 ± 0.13 %). The increase in phosphatidylserine exposure was paralleled by increase in [Ca(2+)]i, oxidative stress, and ceramide abundance. As compared to addition of plasma from healthy individuals, addition of predialytic but not of postdialytic plasma from ESRD patients increased phosphatidylserine exposure, [Ca(2+)]i, ROS, and ceramide abundance. In conclusion, both, dialyzable components of uremic plasma and dialysis procedure, trigger eryptosis at least in part by increasing erythrocyte [Ca(2+)]i, ROS, and ceramide formation.
  
  
  CONCLUSIONS
  Anemia in uremia results in part from eryptosis, the suicidal erythrocyte death. Eryptosis in uremia is triggered in part by a dialyzable plasma component. Eryptosis in uremia is further triggered by dialysis procedure. Eryptosis in uremia is in part due to increased cytosolic Ca(2+) concentration. Eryptosis in uremia is further due to oxidative stress and ceramide formation.
authors.affiliation: Department of Physiology, University of Tuebingen, Gmelinstrasse 5, Tübingen, Germany.
authors.forename: Majed
authors.initials: M
authors.lastname: Abed
authors.forename: Ferruh
authors.initials: F
authors.lastname: Artunc
authors.forename: Kousi
authors.initials: K
authors.lastname: Alzoubi
authors.forename: Sabina
authors.initials: S
authors.lastname: Honisch
authors.forename: Dorothea
authors.initials: D
authors.lastname: Baumann
authors.forename: Michael
authors.initials: M
authors.lastname: Föller
authors.forename: Florian
authors.initials: F
authors.lastname: Lang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017304:Annexin A5 / Q000378:metabolism; D017209:Apoptosis; D002118:Calcium / Q000378:metabolism; D016022:Case-Control Studies; D016923:Cell Death; D002518:Ceramides / Q000096:biosynthesis; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D042541:Intracellular Space / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010718:Phosphatidylserines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D017304:Annexin A5; D002518:Ceramides; D010718:Phosphatidylserines; D017382:Reactive Oxygen Species; D002118:Calcium
references.citation: Semin Nephrol. 2012 Jan;32(1):57-62
references.pmid: 22365163
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):131-42
references.pmid: 19233072
references.citation: Cell Physiol Biochem. 2013;32(4):1106-16
references.pmid: 24217651
references.citation: Semin Dial. 2006 Mar-Apr;19(2):146-51
references.pmid: 16551293
references.citation: J Am Soc Nephrol. 2003 Nov;14(11):2750-7
references.pmid: 14569084
references.citation: Kidney Blood Press Res. 2012;36(1):107-18
references.pmid: 23095759
references.citation: Cell Physiol Biochem. 2013;32(4):801-13
references.pmid: 24080940
references.citation: BMC Nephrol. 2013 Jan 25;14:24
references.pmid: 23351270
references.citation: J Mol Med (Berl). 2006 May;84(5):378-88
references.pmid: 16622713
references.citation: Cell Physiol Biochem. 2011;28(5):847-56
references.pmid: 22178937
references.citation: Kidney Int Suppl. 2010 Aug;(117):S3-9
references.pmid: 20671741
references.citation: Cell Physiol Biochem. 2013;32(5):1426-36
references.pmid: 24296399
references.citation: Int J Biochem Cell Biol. 2012 Aug;44(8):1236-43
references.pmid: 22561748
references.citation: Curr Opin Nephrol Hypertens. 2011 Mar;20(2):177-81
references.pmid: 21157336
references.citation: Kidney Blood Press Res. 2013;37(1):68-83
references.pmid: 23548827
references.citation: Nephrol Dial Transplant. 2007 Oct;22(10):2900-8
references.pmid: 17556407
references.citation: Adv Chronic Kidney Dis. 2011 Nov;18(6):400-5
references.pmid: 22098657
references.citation: Am J Kidney Dis. 2011 Oct;58(4):591-8
references.pmid: 21715072
references.citation: Acta Diabetol. 2013 Aug;50(4):489-95
references.pmid: 21437568
references.citation: Kidney Blood Press Res. 2013;37(6):567-78
references.pmid: 24335488
references.citation: Cell Physiol Biochem. 2013;32(2):291-9
references.pmid: 23942252
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):94-100
references.pmid: 19233068
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):109-16
references.pmid: 19233070
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):83-93
references.pmid: 19233067
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):101-8
references.pmid: 19233069
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):117-30
references.pmid: 19233071
references.citation: Nat Rev Nephrol. 2011 Sep 06;7(11):635-41
references.pmid: 21894183
references.citation: Kidney Blood Press Res. 2013;38(1):42-51
references.pmid: 24556698
references.citation: Nanotoxicology. 2012 Dec;6:847-56
references.pmid: 22022996
references.citation: Free Radic Res. 2013 May;47(5):346-56
references.pmid: 23438723
references.citation: Ann Intern Med. 2010 Jul 6;153(1):23-33
references.pmid: 20439566
references.citation: Cell Physiol Biochem. 2012;30(4):876-88
references.pmid: 22907570
references.citation: Nat Rev Nephrol. 2010 Dec;6(12):699-710
references.pmid: 20956992
references.citation: Kidney Blood Press Res. 2013;37(2-3):158-67
references.pmid: 23712027
references.citation: Am J Physiol Cell Physiol. 2012 Feb 15;302(4):C644-51
references.pmid: 22173866
references.citation: Adv Chronic Kidney Dis. 2009 Mar;16(2):76-82
references.pmid: 19233066
references.citation: Cell Physiol Biochem. 2013;32(6):1600-9
references.pmid: 24335345
references.citation: Curr Opin Nephrol Hypertens. 2010 Sep;19(5):420-4
references.pmid: 20689425
references.citation: Cell Physiol Biochem. 2012;30(3):512-22
references.pmid: 22814298
references.citation: Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1127-34
references.pmid: 17567717